Recombinant Therapeutic Antibodies and Proteins Market to Reach Beyond US$ 250 Billion by 2026

The Global Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 91.2 billion in 2017 and is projected to exhibit a CAGR of 12.2% over the forecast period (2018 – 2026). Recombinant therapeutic antibodies and proteins market is expected to grow at significant rate, owing to increasing advancements in development of recombinant therapeutic drugs.

Increasing focus on recombinant therapeutics for drug development is expected to drive growth of the recombinant therapeutic antibodies and proteins market revenue

Demand for recombinant therapeutic antibodies and proteins is increasing significantly with a constant need to improve the existing expression systems or developing novel approaches to meet the demand for new therapeutics.

Pharmaceutical recombinant protein is increasingly used in treatment of diseases such as cancer, diabetes, anemia, and hepatitis. Medicinal and industrial use of recombinant protein in drug manufacturing is rising along with increasing demand for various protein expression systems and other related high-tech systems. Recombinant therapeutic antibodies and proteins market is expected to exhibit high growth, owing to increasing adoption of protein-engineering technologies and government support for its development.

For instance, in 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for Serious Conditions. It was designed to be available for drugs used to treat a serious illness that have been shown to exhibit clinical evidence of significant improvement in comparison to existing treatments.

Moreover, existing therapies can be optimized to achieve better drug targeting and enhancing functionality and potency by modifying or introducing new drug activities, leading to customization of existing proteins or development of novel therapeutics for specific clinical applications.

Companies are focusing on engineering strategies and rational design to modify drug activity for generation of novel therapeutics related to specific clinical requirements. For instance, in 2015, alirocumab injection (Praluent, Regeneron/Sanofi), the first cholesterol-lowering treatment in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors received FDA approval.

Browse 22 Market Data Tables and 27 Figures spread through 160 Pages and in-depth TOC on “Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026”

To know the latest trends and insights prevalent in the recombinant therapeutic antibodies and proteins market, click the link below:

https://www.coherentmarketinsights.com/market-insight/recombinant-therapeutic-antibodies-and-proteins-market-1981

Key Takeaways of the Recombinant Therapeutic Antibodies and Proteins Market:

• The global recombinant therapeutic antibodies and proteins market size is expected to exhibit a CAGR of 14.2% over the forecast period, owing to increasing focus on recombinant therapeutics for drug development
• Among drug class, the monoclonal antibodies segment is estimated to hold the dominant position in the recombinant therapeutic antibodies and proteins market, in 2017, due increasing applications of mAbs in therapeutics.
• Among application, the hematology segment is estimated to hold the dominant position in the recombinant therapeutic antibodies and proteins market, in 2017, owing to increasing number of approved products available in this category.
• North America holds a dominant position in the global recombinant therapeutic antibodies and proteins market, owing to increasing R&D expenditure and increasing product approvals.
• Key players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.